Patents by Inventor Jane Ennis

Jane Ennis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8900573
    Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also emply soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: December 2, 2014
    Inventors: John E. Davies, Jane Ennis, Alejandro Gomez-Aristiz-Abal, Dolores Baksh
  • Publication number: 20130089565
    Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also emply soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.
    Type: Application
    Filed: September 28, 2012
    Publication date: April 11, 2013
    Inventors: John E. Davies, Jane Ennis, Alejandro Gomez-Aristiz-Abal, Dolores Baksh
  • Patent number: 8277794
    Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: October 2, 2012
    Inventors: John E. Davies, Jane Ennis, Alejandro Gomez-Aristiz-Abal, Dolores Baksh
  • Patent number: 8278102
    Abstract: Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: October 2, 2012
    Inventors: Jane Ennis, Rahul Sarugaser, John E. Davies
  • Publication number: 20090285842
    Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.
    Type: Application
    Filed: May 4, 2007
    Publication date: November 19, 2009
    Inventors: John E. Davies, Jane Ennis, Alejandro Gomez-Aristiz-Abal, Dolores Baksh
  • Publication number: 20090275127
    Abstract: Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.
    Type: Application
    Filed: December 21, 2006
    Publication date: November 5, 2009
    Inventors: Jane Ennis, Rahul Sarugaser, John E. Davies